The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
细胞周期蛋白依赖性激酶抑制剂 p57（Kip2）在卡铂耐药中受表观遗传调控，并导致卵巢癌对 CDK 抑制剂 seliciclib 产生附带敏感性
期刊:British Journal of Cancer
影响因子:6.4
doi:10.1038/bjc.2011.566
H M Coley, N A M Safuwan, P Chivers, E Papacharalbous, T Giannopoulos, S Butler-Manuel, K Madhuri, D P Lovell, T Crook
